Relief Therapeutics Holding SA (OTCMKTS:RLFTF) Short Interest Up 52.6% in July

Relief Therapeutics Holding SA (OTCMKTS:RLFTF) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 48,493 shares, a growth of 52.6% from the July 15th total of 31,784 shares. Based on an average daily volume of 11,695 shares, the days-to-cover ratio is currently 4.1 days.

Relief Therapeutics Stock Performance

OTCMKTS:RLFTF opened at $0.32 on Wednesday. The business has a 50 day simple moving average of $0.27 and a 200 day simple moving average of $0.55. Relief Therapeutics has a 12-month low of $0.16 and a 12-month high of $4.88.

Relief Therapeutics Company Profile

Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.

The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.